Definitive Contract HDTRA114C0045

This is a $60,427,361.98 Other Transaction Agreement (OTA) for prototype development of an Ebola virus product, awarded by the Joint PEO Chemical and Biological Defense (part of the U.S. Department of Defense) to Gilead Sciences Inc., a prominent biopharmaceutical company. The contract has an ultimate completion date of June 30, 2025 and does not use a small business set-aside. Gilead is the prime contractor, and there is no information provided about any subcontractors. This award is part of...

This is a $762,812,695.00 firm fixed price contract awarded by the U.S. Department of Health and Human Services' (HHS) Biomedical Advanced Research and Development Authority (BARDA) to Emergent Product Development Gaithersburg Inc., a for-profit manufacturer of medical countermeasures. The contract is for the development of medical countermeasures that can be deployed in the event of a filovirus outbreak, which is a crucial component of the U.S. government's outbreak response plan. The...

This is a delivery order awarded under the Homeland Defense and Security Technical Area Tasks (HD TATs) IDIQ contract, issued by the U.S. Air Force Materiel Command. The $5,256,015.00 contract was awarded to Battelle Memorial Institute, a non-profit research and development organization, to provide Ebola diagnostics, field analytics, and sequencing support for the Joint Product Manager Medical Countermeasure Systems. Luminex Corporation, a manufacturer of biological testing technologies, was...

This is a $62,511,942.00 cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services, to Mapp Biopharmaceutical, Inc., a biotechnology company based in San Diego, California. The contract is for the development of an anti-Sudan ebolavirus medical countermeasure, a critical public health and national security priority. Mapp Biopharmaceutical has a strong...

This is a federal contract awarded by the Defense Threat Reduction Agency (DTRA), a defense agency, to Mapp Biopharmaceutical, Inc., a biotechnology company specializing in the development of antibody-based therapeutics and medical countermeasures against infectious diseases and biothreats. The contract, valued at $6,173,324.00, is for research and development services during the base period, with a period of performance ending on August 31, 2017. The contract is a Cost Plus Fixed Fee Definitive...

This is a delivery order issued against the Homeland Defense and Security Technical Area Tasks (HD TATs) indefinite-delivery indefinite-quantity (IDIQ) contract, which is held by the U.S. Air Force Materiel Command. The $12,284,540.00 contract was awarded to Battelle Memorial Institute, a non-profit research and development organization, to support the Joint Vaccine Acquisitions Program's advanced filovirus vaccine development and continued medical countermeasures research. The contract involves...

This $38,243,034.02 cost-plus-fixed-fee contract was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Mapp Biopharmaceutical, Inc., a biotechnology company specializing in antibody-based therapeutics and medical countermeasures against infectious diseases and biothreats. The contract, which has no set-aside designation, is for the development of medical countermeasures through planned clinical trials and outbreak preparedness. This contract builds on...

This federal contract award, with ID HDTRA116C0025, was issued by the Defense Threat Reduction Agency (DTRA) to The Trustees of Princeton University, a private non-profit research university, for the development of an "Ultrasensitive Rapid Ebola Virus Antigen Diagnostic Assay" during the base period. The $5,567,820.56 definitive contract has a cost-no-fee pricing type and a completion date of October 1, 2019. It did not have a set-aside designation. The prime contractor, Princeton...

This is a $2,594,319.91 federal contract awarded by the Defense Threat Reduction Agency (DTRA) to Microbiotix, Inc., a clinical-stage biopharmaceutical company. The contract is for the development of novel small molecule therapeutics to treat infections by Ebola and Marburg viruses. The contract is a Definitive Contract with a Cost Plus Fixed Fee pricing type, with a period of performance ending on December 14, 2020. Microbiotix has subcontracted with the Albert Einstein College of Medicine...

This is a federal contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency within the U.S. Department of Health and Human Services, to Profectus Biosciences, Inc., a small business contractor. The contract is a Definitive Contract with a Cost Plus Fixed Fee pricing type, with a ceiling value of $7,524,330.27 and a period of performance through November 30, 2016. The contract is for the GMP (Good Manufacturing Practice) manufacture of the...